Abstract:Inhibition of clonogenic potential by the glycinamideribonucleosyl transformylase inhibitor 5,10-dideazatetrahydrofolic acid (DDATHF, Lometrexol) was evaluated in vitro in a human ovarian carcinoma cell line, SW626. Drug-induced inhibition of clonogenic potential is a function of the dose and time of exposure and is independent of the formation of DNA single-strand breaks or de novo synthesis of protein. Simultaneous treatment with 100 microM hypoxanthine completely prevented the inhibition of clonogenic potential caused by 0.5 microM DDATHF. DDATHF blocked cells in the early-middle S-phases of the cell cycle, and there was a corresponding marked reduction in the rate of DNA synthesis after drug withdrawal. The cytotoxic potential of DDATHF was modulated by the folic acid concentration present in the medium. In a medium containing 0.22 microM folic acid, DDATHF cytotoxicity was at least 100 times that in a regular medium containing 2.22 microM folic acid, levels which, however, are about 100 times those found in human plasma. DDATHF cytotoxicity differed moderately when folic acid concentrations varied between 0.22 and 0 microM, suggesting that folic acid does not necessarily antagonise DDATHF anti-tumour activity. Folinic acid at a concentration as low as 0.1 microM can completely rescue cells when given simultaneously with 0.5 microM DDATHF. When folinic acid was given 24 h after DDATHF, a reversal of cytotoxicity was observed at 0.5 and 1 microM, but to a much lesser extent than simultaneous treatment. When folinic acid was added after 48 or 72 h of DDATHF washout, even at a high concentration and for a long time, no reduction in DDATHF cytotoxicity was found. In conclusion, the study highlights the modulation of DDATHF cytotoxicity by folic acid or by folinic acid and provides further rationale for in vivo clinical investigation with these combinations.

Synthesis of aza homologues of folic acid.

Synthesis and Bioactivity of N-5-Substituted 4-Amino-N-8,N-10-deazatetrahydrofolate Analogues

Design, Synthesis, and Anticancer Activity Evaluation of Hybrids of Azoles and Barbituric Acids.

Design, synthesis, and biological evaluation of novel carbazole aminothiazoles as potential DNA-targeting antimicrobial agents

Synthesis, Antifolate and Anticancer Activities of N(5) -Substituted 8,10-Dideazatetrahydrofolate Analogues.

Synthesis and Bioactivity of 8-Deaza Folic Acid Analogues of Thiophene

Studies On Synthesis And Bioactivity Of N-8-Deaza-N-5-Tetrahydrofolate Analogues

Synthesis of Flavone Derivatives via N-Amination and Evaluation of Their Anticancer Activities

Novel 8-deaza-5,6,7,8-tetrahydroaminopterin derivatives as dihydrofolate inhibitor: design, synthesis and antifolate activity.

A Novel Kind of Antitumour Drugs Using Sulfonamide As Parent Compound

Novel Synthesis of 8-Deaza-5,6,7,8-tetrahydroaminopterin Analogues via an Aziridine Intermediate

Synthesis of Novel Spin-Labeled Derivatives of 5-FU As Potential Antineoplastic Agents

Synthesis and Antitumor Activity of a Novel Series of 6-Substituted Pyrrolo[2,3-D]pyrimidines As Potential Nonclassical Antifolates Targeting Both Thymidylate and Purine Nucleotide Biosynthesis.

A Novel Synthesis of Diethyl 4-Amino-8-deazatetrafolate

Design, Synthesis and Activities of Aziridine Derivatives of N 5 -Methyltetrahydrofolate Against Methionine Synthase

Synthesis and Antitumor Activity of Novel Pyrimidine Monocyclic Nonclassical Antifolates

Mechanism-Based Design, Synthesis and Biological Studies of N-5-Substituted Tetrahydrofolate Analogs As Inhibitors of Cobalamin-Dependent Methionine Synthase and Potential Anticancer Agents

Synthesis of fluorinated amino acids by low-specificity, promiscuous aldolases coupled to in situ fluorodonor generation

Synthesis and Antitumor Activity Evaluation of Γ‐monofluorinated and Γ,γ‐difluorinated Goniothalamin Analogues

Mechanism of cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cells in vitro and modulation of the drug activity by folic or folinic acid

Synthesis and anticancer activity of new azo compounds containing extended π-conjugated systems